'Misinformation': AstraZeneca's China head refutes news report about potential spinoff

With the help of bankers, the British drugmaker has worked out a plan to potentially spin its China business into a separate entity listed in Hong Kong while retaining control, the Financial Times reports, citing people familiar with the discussions.

A separation might not eventually take place, the people said. One of the people said listing in Shanghai is also an option.